Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transanal Minimally Invasive TME (TaTME) Versus Open Intersphincteric Resection and Total Mesorectal Excision of Stage II/III Ultralow Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy.

NCT01836926 is registered in ClinicalTrials.gov with Osama Mohammad Ali ElDamshety as lead sponsor.

NCT NCT01836926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transanal Minimally Invasive TME (TaTME) Versus Open Intersphincteric Resection and Total Mesorectal Excision of Stage II/III Ultralow Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy.
Lead sponsor
Osama Mohammad Ali ElDamshety
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2013
Completion date
July 31, 2019
Enrollment
110 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer